A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors.

Trial Profile

A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs CUDC 101 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Curis
  • Most Recent Events

    • 16 Nov 2010 Results will be presented in a poster session at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 13 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2010 Status changed from planning to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top